Vanessa Mettmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Vanessa Mettmann has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Benjamin Sorg
Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart Cancer Center, Zentrum für Kinder‐, Jugend‐ und Frauenmedizin Klinikum Stuttgart – Olgahospital Stuttgart Germany
6 shared publications- Leo Kager
St. Anna Children’s Cancer Research Institute, Vienna, Austria
6 shared publications Matthias Kevric
Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart Cancer Center, Zentrum für Kinder‐, Jugend‐ und Frauenmedizin Klinikum Stuttgart – Olgahospital Stuttgart Germany
6 shared publications- Stefan Bielack
Klinikum Stuttgart – Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart, Germany
6 shared publications - Claudia Blattmann
Klinikum Stuttgart – Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart, Germany
5 shared publications - Thomas Kühne
Department of Hematology/Oncology, University Children’s Hospital Basel, Basel, Switzerland
4 shared publications
Latest Publications
- Open Access
- 9 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (17) , e71211
Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group ( COSS )
Purpose: Teleangiectatic osteosarcoma is a histologic subtype of osteosarcoma that can mimic aneurysmal bone cysts and has so far been incompletely characterized. Patients and Methods: We used the database of the Cooperative Osteosarcoma Study Group COSS (patient‐registration 1980–2019) to better understand this rare histologic variant. Results: 223 eligible patients were identified, 164 having reference pathology (median age 15.9 (3.7–69.7) years; male 134, female 89; tumor sites limb 208 (201 metaphyses, 66 pathologic fractures), trunk 13, head & neck 2; 26 with primary metastases). Known tumor‐predisposition syndromes were rare. Therapy included surgery in 215, radiotherapy in 10, and chemotherapy in all patients. Tumor response to preoperative treatment was good in 71% of 165 cases with available data. After a median follow‐up of 7.1 (0.2–32.1) years for all patients and 10.5 (0.2–32.1) years for 152 survivors, 5‐/10‐year actuarial event‐free and overall survival expectancies were 61%/57% and 73%/66%, respectively. Five unrelated malignancies occurred during this period. The presence of primary metastases, pathologic fracture, poor response to neoadjuvant chemotherapy, and not obtaining a complete macroscopic remission were associated with inferior outcomes for both event‐free and overall survival ( p < 0.01). Discussion: This large analysis proves teleangiectatic osteosarcoma to be a disease predominantly of the metaphyses of the young. While detected only rarely, the true incidence of genetic tumor predispositions would require prospective assessments. Behaving like other osteosarcoma subtypes in many other ways, this variant may show greater chemosensitivity and hence somewhat better outcomes than other subtypes.
- 9 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (17) , e71211
Open AccessTeleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group ( COSS )
Purpose: Teleangiectatic osteosarcoma is a histologic subtype of osteosarcoma that can mimic aneurysmal bone cysts and has so far been incompletely characterized. Patients and Methods: We used the database of the Cooperative Osteosarcoma Study Group COSS (patient‐registration 1980–2019) to better understand this rare histologic variant. Results: 223 eligible patients were identified, 164 having reference pathology (median age 15.9 (3.7–69.7) years; male 134, female 89; tumor sites limb 208 (201 metaphyses, 66 pathologic fractures), trunk 13, head & neck 2; 26 with primary metastases). Known tumor‐predisposition syndromes were rare. Therapy included surgery in 215, radiotherapy in 10, and chemotherapy in all patients. Tumor response to preoperative treatment was good in 71% of 165 cases with available data. After a median follow‐up of 7.1 (0.2–32.1) years for all patients and 10.5 (0.2–32.1) years for 152 survivors, 5‐/10‐year actuarial event‐free and overall survival expectancies were 61%/57% and 73%/66%, respectively. Five unrelated malignancies occurred during this period. The presence of primary metastases, pathologic fracture, poor response to neoadjuvant chemotherapy, and not obtaining a complete macroscopic remission were associated with inferior outcomes for both event‐free and overall survival ( p < 0.01). Discussion: This large analysis proves teleangiectatic osteosarcoma to be a disease predominantly of the metaphyses of the young. While detected only rarely, the true incidence of genetic tumor predispositions would require prospective assessments. Behaving like other osteosarcoma subtypes in many other ways, this variant may show greater chemosensitivity and hence somewhat better outcomes than other subtypes.
- Open Access
- 29 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31344
Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)
Background: Osteosarcoma may arise as a secondary malignancy following rhabdomyosarcoma (RMS). We utilized the Cooperative Osteosarcoma Study Group (COSS) database to better understand this association. Patients and methods: The COSS database (1980‐05/2023) was searched for patients whose osteosarcoma was preceded by RMS. Eligible patients were analyzed for patient‐, tumor‐, and treatment‐related variables as well as outcomes. Results: The search revealed 28 eligible osteosarcomas (27 high‐grade central, one periosteal; male:female = 16:12; median age RMS 2.1 [range: 0.9–10.0] years, osteosarcoma 13.5 [7.2–29.0] years). Genetic tumor‐predisposition syndromes were documented in 12 patients. One patient had had a distinct malignancy prior to RMS, two intermittently, seven following osteosarcoma. Local RMS treatment had included radiotherapy in 20/26 cases (two unknown). Secondary osteosarcoma sites were extremity 13, trunk seven, head and neck eight; 15 osteosarcomas were radiation‐associated. There was only one case of primary osteosarcoma metastases. Osteosarcoma treatment included chemotherapy (27), surgery (26), or radiotherapy (2). A macroscopically complete remission of all osteosarcoma sites was achieved in 24 cases. Median follow‐up was 5.8 (range: 0.5–18.4) years after osteosarcoma and 8.1 (1.0–15.4) years for 14 survivors. Actuarial 5‐year overall and event‐free survival were 66% (standard error 9%) and 45% (10%), respectively. Five of 14 deaths were caused by further malignancies. Conclusion: This series offers a benchmark for patients who develop a secondary osteosarcoma after RMS. Affected patients are generally still in the pediatric age. The results obtained strongly argue for genetic predisposition testing in RMS and against therapeutic leniency in comparable situations.
- 29 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31344
Open AccessOsteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)
Background: Osteosarcoma may arise as a secondary malignancy following rhabdomyosarcoma (RMS). We utilized the Cooperative Osteosarcoma Study Group (COSS) database to better understand this association. Patients and methods: The COSS database (1980‐05/2023) was searched for patients whose osteosarcoma was preceded by RMS. Eligible patients were analyzed for patient‐, tumor‐, and treatment‐related variables as well as outcomes. Results: The search revealed 28 eligible osteosarcomas (27 high‐grade central, one periosteal; male:female = 16:12; median age RMS 2.1 [range: 0.9–10.0] years, osteosarcoma 13.5 [7.2–29.0] years). Genetic tumor‐predisposition syndromes were documented in 12 patients. One patient had had a distinct malignancy prior to RMS, two intermittently, seven following osteosarcoma. Local RMS treatment had included radiotherapy in 20/26 cases (two unknown). Secondary osteosarcoma sites were extremity 13, trunk seven, head and neck eight; 15 osteosarcomas were radiation‐associated. There was only one case of primary osteosarcoma metastases. Osteosarcoma treatment included chemotherapy (27), surgery (26), or radiotherapy (2). A macroscopically complete remission of all osteosarcoma sites was achieved in 24 cases. Median follow‐up was 5.8 (range: 0.5–18.4) years after osteosarcoma and 8.1 (1.0–15.4) years for 14 survivors. Actuarial 5‐year overall and event‐free survival were 66% (standard error 9%) and 45% (10%), respectively. Five of 14 deaths were caused by further malignancies. Conclusion: This series offers a benchmark for patients who develop a secondary osteosarcoma after RMS. Affected patients are generally still in the pediatric age. The results obtained strongly argue for genetic predisposition testing in RMS and against therapeutic leniency in comparable situations.
- Open Access
- 31 March 2024
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 3
Osteosarcomas in retinoblastoma-survivors. A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)
- 31 March 2024
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 3
Open AccessOsteosarcomas in retinoblastoma-survivors. A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS)
- Open Access
- 29 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (1) , e6893
Beyond 5‐year survival. A report from the Cooperative Osteosarcoma Study Group (COSS)
Purpose: Prognostic factors have been well described for osteosarcoma, but analyses evaluating the further course of long‐term survivors are lacking. We used the large database of the Cooperative Osteosarcoma Study Group (COSS) to perform such an analysis.Patients and Methods: The COSS database 1980‐04/2019 was searched for 5‐year survivors of primary high‐grade central osteosarcoma of the extremities or trunk. Identified patients were analyzed for their further survival outcomes, assessing potentially prognostic and predictive factors already evident at initial disease presentation and treatment as well as their disease course during the first 5 years of follow‐up.Results: Two thousand and nine former eligible patients were identified (median age at initial diagnosis 15.1 (2.5–63.0) years; male vs. female 1149 (57.2%) vs. 860 (42.8%); extremities vs. trunk 1927 (95.9%) vs. 82 (4.1%); extremity primaries p < 0.001). Significant predictors of survival for all patients age at diagnosis (p = 0.038), tumor site (p = 0.030), having experienced the osteosarcoma as secondary malignancy (p < 0.001), tumor response to preoperative chemotherapy (p = 0.002). Multivariate Cox regression testing possible for 1759 (87.6%) patients with complete dataset: Having had a recurrence in years 1–5 (p < 0.001), older age at diagnosis (p = 0.009), and osteosarcoma as secondary malignancy (p = 0.013) retained significance.Discussion: Highly important predictors of death such as the extent of tumor response to chemotherapy no longer remain valid after 5‐year survival. The individual history of malignancies and their outcomes seems to gain pivotal importance.Conclusion: This benchmark analysis clearly defined risk factors for the further course of 5‐year survivors from osteosarcoma. It argues for large disease‐oriented databases as well as for very long follow‐up periods. Novel findings will most likely require innovative statistical models to analyze such cohorts.
- 29 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (1) , e6893
Open AccessBeyond 5‐year survival. A report from the Cooperative Osteosarcoma Study Group (COSS)
Purpose: Prognostic factors have been well described for osteosarcoma, but analyses evaluating the further course of long‐term survivors are lacking. We used the large database of the Cooperative Osteosarcoma Study Group (COSS) to perform such an analysis.Patients and Methods: The COSS database 1980‐04/2019 was searched for 5‐year survivors of primary high‐grade central osteosarcoma of the extremities or trunk. Identified patients were analyzed for their further survival outcomes, assessing potentially prognostic and predictive factors already evident at initial disease presentation and treatment as well as their disease course during the first 5 years of follow‐up.Results: Two thousand and nine former eligible patients were identified (median age at initial diagnosis 15.1 (2.5–63.0) years; male vs. female 1149 (57.2%) vs. 860 (42.8%); extremities vs. trunk 1927 (95.9%) vs. 82 (4.1%); extremity primaries p < 0.001). Significant predictors of survival for all patients age at diagnosis (p = 0.038), tumor site (p = 0.030), having experienced the osteosarcoma as secondary malignancy (p < 0.001), tumor response to preoperative chemotherapy (p = 0.002). Multivariate Cox regression testing possible for 1759 (87.6%) patients with complete dataset: Having had a recurrence in years 1–5 (p < 0.001), older age at diagnosis (p = 0.009), and osteosarcoma as secondary malignancy (p = 0.013) retained significance.Discussion: Highly important predictors of death such as the extent of tumor response to chemotherapy no longer remain valid after 5‐year survival. The individual history of malignancies and their outcomes seems to gain pivotal importance.Conclusion: This benchmark analysis clearly defined risk factors for the further course of 5‐year survivors from osteosarcoma. It argues for large disease‐oriented databases as well as for very long follow‐up periods. Novel findings will most likely require innovative statistical models to analyze such cohorts.
- Open Access
Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group
Background: To evaluate patient and tumour characteristics, treatment, and their impact on survival in patients with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma. Precedure: Eighty-three consecutive patients who presented with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma were retrospectively reviewed. In cases of curative intent, the Cooperative Osteosarcoma Study Group recommended surgical removal of all detectable metastases in addition to complete resection of the primary tumour and chemotherapy. Results: Eighty-three eligible patients (1.8%) were identified among a total of 4605 individuals with high-grade osteosarcoma. Nine (10.8%) of these achieved complete surgical remission, of whom seven later had recurrences. The median follow-up time was 12 (range, 1–165) months for all patients. Actuarial event-free survival after 1, 2, and 5 years was 9.6 ± 3.2%, 1.4 ± 1.4%, and 1.4 ± 1.4%, and overall survival was 54.0 ± 5.6%, 23.2 ± 4.9%, and 8.7 ± 3.3%. In univariate analyses, elevated alkaline phosphatase before chemotherapy, pleural effusion, distant bones as metastatic sites, and more than one bone metastasis were negative prognostic factors. Among treatment-related factors, the microscopically complete resection of the primary tumour, a good response to first-line chemotherapy, the macroscopically complete resection of all affected tumour sites, and local treatment (surgery ± radiotherapy) of all bone metastases were associated with better outcomes. Tumour progression under first-line treatment significantly correlated with shorter survival times. Conclusion: The outlook for patients with multi-systemic primary metastases from osteosarcoma remains very poor. The utmost importance of surgical resection of all tumour sites was confirmed. For unresectable bone metastases, radiotherapy might be considered. In the patient group studied, standard chemotherapy was often insufficiently effective. In the case of such advanced disease, alternative treatment options are urgently required.
Open AccessPrimary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group
Background: To evaluate patient and tumour characteristics, treatment, and their impact on survival in patients with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma. Precedure: Eighty-three consecutive patients who presented with multi-systemic metastases at initial diagnosis of high-grade osteosarcoma were retrospectively reviewed. In cases of curative intent, the Cooperative Osteosarcoma Study Group recommended surgical removal of all detectable metastases in addition to complete resection of the primary tumour and chemotherapy. Results: Eighty-three eligible patients (1.8%) were identified among a total of 4605 individuals with high-grade osteosarcoma. Nine (10.8%) of these achieved complete surgical remission, of whom seven later had recurrences. The median follow-up time was 12 (range, 1–165) months for all patients. Actuarial event-free survival after 1, 2, and 5 years was 9.6 ± 3.2%, 1.4 ± 1.4%, and 1.4 ± 1.4%, and overall survival was 54.0 ± 5.6%, 23.2 ± 4.9%, and 8.7 ± 3.3%. In univariate analyses, elevated alkaline phosphatase before chemotherapy, pleural effusion, distant bones as metastatic sites, and more than one bone metastasis were negative prognostic factors. Among treatment-related factors, the microscopically complete resection of the primary tumour, a good response to first-line chemotherapy, the macroscopically complete resection of all affected tumour sites, and local treatment (surgery ± radiotherapy) of all bone metastases were associated with better outcomes. Tumour progression under first-line treatment significantly correlated with shorter survival times. Conclusion: The outlook for patients with multi-systemic primary metastases from osteosarcoma remains very poor. The utmost importance of surgical resection of all tumour sites was confirmed. For unresectable bone metastases, radiotherapy might be considered. In the patient group studied, standard chemotherapy was often insufficiently effective. In the case of such advanced disease, alternative treatment options are urgently required.
- Open Access
- 7 August 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (17) , 18219-18234
Solitary pulmonary metastases at first recurrence of osteosarcoma: Presentation, treatment, and survival of 219 patients of the Cooperative Osteosarcoma Study Group
Background: To evaluate patient and tumour characteristics, treatment and their impact on survival in patients with a solitary pulmonary metastasis at first relapse of high‐grade osteosarcoma.Procedure: Two‐hundred and nineteen consecutive patients who had achieved a complete surgical remission and then developed a solitary pulmonary metastasis at first recurrence of high‐grade osteosarcoma were retrospectively reviewed.Results: Two hundred and three (94.9%) of 214 patients achieved a second complete remission. After a median time from initial diagnosis of osteosarcoma to first relapse of 2.3 years (range, 0.3–18.8 years), actuarial post‐relapse overall survival after 2 and 5 years was 72.0% and 51.2%. Post‐relapse event‐free survival was 39.1% and 31.1%. Median follow‐up time was 3.2 years (range, 0.1–29.4 years). A longer time until first relapse and diagnosis due to imaging were positive prognostic factors in uni‐ and multivariate analyses, as were a second complete surgical remission and, in regard to death, the absence of a subsequent relapse. The use of salvage chemotherapy and radiotherapy were not associated with patient outcomes, nor was the surgical approach (thoracoscopy vs. thoracotomy) nor the exploration (uni‐ vs. bilateral).Conclusion: Approximately half of the patients who experience a solitary pulmonary relapse at first recurrence of osteosarcoma remain alive 5 years after this first relapse. Only one third will remain disease‐free. A complete surgical resection of the lesion is essential for long‐term survival while relapse chemotherapy does not seem to improve survival. Innovative therapies are required to improve outcomes.
- 7 August 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (17) , 18219-18234
Open AccessSolitary pulmonary metastases at first recurrence of osteosarcoma: Presentation, treatment, and survival of 219 patients of the Cooperative Osteosarcoma Study Group
Background: To evaluate patient and tumour characteristics, treatment and their impact on survival in patients with a solitary pulmonary metastasis at first relapse of high‐grade osteosarcoma.Procedure: Two‐hundred and nineteen consecutive patients who had achieved a complete surgical remission and then developed a solitary pulmonary metastasis at first recurrence of high‐grade osteosarcoma were retrospectively reviewed.Results: Two hundred and three (94.9%) of 214 patients achieved a second complete remission. After a median time from initial diagnosis of osteosarcoma to first relapse of 2.3 years (range, 0.3–18.8 years), actuarial post‐relapse overall survival after 2 and 5 years was 72.0% and 51.2%. Post‐relapse event‐free survival was 39.1% and 31.1%. Median follow‐up time was 3.2 years (range, 0.1–29.4 years). A longer time until first relapse and diagnosis due to imaging were positive prognostic factors in uni‐ and multivariate analyses, as were a second complete surgical remission and, in regard to death, the absence of a subsequent relapse. The use of salvage chemotherapy and radiotherapy were not associated with patient outcomes, nor was the surgical approach (thoracoscopy vs. thoracotomy) nor the exploration (uni‐ vs. bilateral).Conclusion: Approximately half of the patients who experience a solitary pulmonary relapse at first recurrence of osteosarcoma remain alive 5 years after this first relapse. Only one third will remain disease‐free. A complete surgical resection of the lesion is essential for long‐term survival while relapse chemotherapy does not seem to improve survival. Innovative therapies are required to improve outcomes.
- Open Access
Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS)
Introduction: Osteosarcoma treatment has benefitted greatly from collaborative research. This paper describes the history and accomplishments of the Cooperative Osteosarcoma Study Group (COSS), mainly dedicated to clinical questions, as well as remaining challenges. Materials and Methods: Narrative review of over four decades of uninterrupted collaboration within the multi-national German–Austrian–Swiss COSS group. Results: Since its very first prospective osteosarcoma trial starting in 1977, COSS has continuously been able to provide high-level evidence on various tumor- and treatment-related questions. This includes both the cohort of patients enrolled into prospective trials as well as those patients excluded from them for various reasons, followed in a prospective registry. Well over one hundred disease-related publications attest to the group’s impact on the field. Despite these accomplishments, challenging problems remain. Discussion: Collaborative research within a multi-national study group resulted in better definitions of important aspects of the most common bone tumor, osteosarcoma, and its treatments. Important challenges continue to persist.
Open AccessEstablishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS)
Introduction: Osteosarcoma treatment has benefitted greatly from collaborative research. This paper describes the history and accomplishments of the Cooperative Osteosarcoma Study Group (COSS), mainly dedicated to clinical questions, as well as remaining challenges. Materials and Methods: Narrative review of over four decades of uninterrupted collaboration within the multi-national German–Austrian–Swiss COSS group. Results: Since its very first prospective osteosarcoma trial starting in 1977, COSS has continuously been able to provide high-level evidence on various tumor- and treatment-related questions. This includes both the cohort of patients enrolled into prospective trials as well as those patients excluded from them for various reasons, followed in a prospective registry. Well over one hundred disease-related publications attest to the group’s impact on the field. Despite these accomplishments, challenging problems remain. Discussion: Collaborative research within a multi-national study group resulted in better definitions of important aspects of the most common bone tumor, osteosarcoma, and its treatments. Important challenges continue to persist.
- 7 March 2022
- Published by Springer Nature in Monatsschrift Kinderheilkunde
- Vol. 170 (4) , 357-358
Erratum zu: Abstracts der 95. Wissenschaftlichen Tagung der Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)
- 7 March 2022
- Published by Springer Nature in Monatsschrift Kinderheilkunde
- Vol. 170 (4) , 357-358
Erratum zu: Abstracts der 95. Wissenschaftlichen Tagung der Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)